Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

First-in-class pan-RAS(ON) ADC is cleared for clinical development

Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity.